NUWE
What one share of Nuwellis holds
Electromedical and Electrotherapeutic Apparatus
Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the “Aquadex System”).
Nuwellis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $12.05 |
|---|---|
| Profit | −$15.14 |
| Capex (buildings and equipment) | $0.17 |
| Free cash flow | −$16.83 |
| Cash and investments | $6.83 |
| Book value | −$3.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $451.24 | −$1,067 | $18.07 | −$1,023 | — | $596.40 |
| 2021 | $114.80 | −$284.35 | $3.17 | −$261.77 | — | $246.23 |
| 2022 | $49.14 | −$83.55 | $0.70 | −$87.84 | — | — |
| 2023 | $157.93 | −$360.06 | $2.65 | −$322.24 | — | — |
| 2024 | $276.57 | −$353.31 | $1.90 | −$305.40 | — | — |
| 2025 | $11.98 | −$25.39 | $0.13 | −$15.79 | — | $54.54 |